147 related articles for article (PubMed ID: 17162628)
1. Depression and psoriasis comorbidity. Treatment with paroxetine: two case reports.
Luis Blay S
Ann Clin Psychiatry; 2006; 18(4):271-2. PubMed ID: 17162628
[No Abstract] [Full Text] [Related]
2. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
[TBL] [Abstract][Full Text] [Related]
3. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
Hwang JP; Yang CH; Tsai SJ
Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
[No Abstract] [Full Text] [Related]
4. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
[TBL] [Abstract][Full Text] [Related]
5. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
6. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
7. Should adjunctive antipsychotic treatment be continued in remitted patients with depression?
Uchida H; Suzuki T; Watanabe K; Kashima H
Psychiatry Clin Neurosci; 2009 Feb; 63(1):126. PubMed ID: 19154222
[No Abstract] [Full Text] [Related]
8. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
Schönfeldt-Lecuona C; Connemann BJ; Wolf RC; Braun M; Freudenmann RW
Pharmacopsychiatry; 2006 Jul; 39(4):152-4. PubMed ID: 16871471
[TBL] [Abstract][Full Text] [Related]
9. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
[TBL] [Abstract][Full Text] [Related]
10. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
11. Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women.
Mück-Seler D; Sagud M; Mihaljevi-Peles A; Jakovljevi M; Pivac N
J Clin Psychopharmacol; 2011 Jun; 31(3):387-90. PubMed ID: 21532370
[No Abstract] [Full Text] [Related]
12. Time course of response to paroxetine: influence of plasma level.
Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G
Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353
[TBL] [Abstract][Full Text] [Related]
13. Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure.
Chuang YF; Chiu YL; Hwang TJ; Chu TS
Psychiatry Clin Neurosci; 2006 Oct; 60(5):642-3. PubMed ID: 16958954
[No Abstract] [Full Text] [Related]
14. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
15. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder.
Ballesteros J; Callado LF; Gutiérrez M
J Clin Psychopharmacol; 2007 Apr; 27(2):219-21. PubMed ID: 17414254
[No Abstract] [Full Text] [Related]
16. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
17. Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.
Argyropoulos SV; Hicks JA; Nash JR; Bell CJ; Rich AS; Nutt DJ; Wilson S
J Sleep Res; 2009 Sep; 18(3):342-8. PubMed ID: 19549078
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
19. A rare case of male hysteria - hemiparesis successfully treated with amitriptyline.
Miljevic CD; Kecojevic-Miljevic S; Crnobaric C; Lecic-Tosevski D
Psychiatr Danub; 2011 Sep; 23(3):281-4. PubMed ID: 21963697
[No Abstract] [Full Text] [Related]
20. [Severe forms of depression: the efficacy of escitalopram].
Spadone C
Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
